Trailing-twelve-month (TTM) revenue is $38.13 Billion with a year-over-year growth of +9.23%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $9,557,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $9,896,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-13 |
| Q1 FY2026Period ended 2026-03-31 | $8,618,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-30 |
| Q2 FY2026Period ended 2026-06-30 | $10,054,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $38,125,000,000 |
Current P/S: $202,741,310,200 market capitalization ÷ $38,125,000,000 TTM revenue = 5.32x.
Market capitalization source: FMP quote. Quote observed 2026-09-15T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $10.05B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-16T10:20:27.354Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Aranesp | $1.6B | $1.5B | $1.4B | $1.4B | $1.3B | $1.4B |
| BLINCYTO | N/A | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Non-US | $6.9B | $7.8B | $7.7B | $8.4B | $9.6B | $10.3B |
| UNITED STATES | $18.5B | $18.2B | $18.6B | $19.8B |
$38.13B
$38.13 Billion
+9.23%
vs. $34.90B a year ago (TTM)
+8.39%
5 Year compound annual growth rate
1 Year
+9.23%
3 Year
+12.77%
5 Year
+8.39%
10 Year
+5.43%
15 Year
+6.27%
20 Year
+5.43%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $36.74B | +$3.32B | +9.92% |
| 2024 | $33.42B | +$5.23B | +18.57% |
| 2023 | $28.19B | +$1.87B | +7.09% |
| 2022 | $26.32B | +$344.00M | +1.32% |
| 2021 | $25.98B | +$555.00M | +2.18% |
| 2020 |
TTM Growth
+9.23%
3-Year CAGR
+12.77%
5-Year CAGR
+8.39%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-16T10:20:27.354Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $1.2B |
| $1.6B |
| ENBREL | $5.0B | $4.5B | $4.1B | $3.7B | $3.3B | $2.2B |
|---|
| Evenity | N/A | N/A | $787M | $1.2B | N/A | N/A |
|---|
| EVENITY | N/A | N/A | N/A | N/A | $1.6B | $2.1B |
|---|
| KRYSTEXXA | N/A | N/A | N/A | $272M | $1.2B | $1.3B |
|---|
| Kyprolis | $1.1B | $1.1B | $1.2B | $1.4B | $1.5B | N/A |
|---|
| Neulasta | $2.3B | $1.7B | $1.1B | N/A | N/A | N/A |
|---|
| Nplate | N/A | $1.0B | $1.3B | $1.5B | $1.5B | $1.5B |
|---|
| Otezla | $2.2B | $2.2B | $2.3B | $2.2B | $2.1B | $2.3B |
|---|
| Other Products | $6.6B | $5.9B | $5.6B | $5.3B | $5.6B | $7.3B |
|---|
| Product and Service, Other | $1.2B | $1.7B | $1.5B | $1.3B | $1.4B | $1.6B |
|---|
| Prolia | $2.8B | $3.2B | $3.6B | $4.0B | $4.4B | $4.4B |
|---|
| Repatha | N/A | N/A | N/A | N/A | N/A | $3.0B |
|---|
| Repatha (evolocumab) | $887M | $1.1B | $1.3B | $1.6B | $2.2B | N/A |
|---|
| TEPEZZA | N/A | N/A | N/A | $448M | $1.9B | $1.9B |
|---|
| TEZSPIRE | N/A | N/A | N/A | N/A | $972M | $1.5B |
|---|
| Vectibix | N/A | N/A | N/A | $984M | $1.0B | $1.2B |
|---|
| XGEVA | $1.9B | $2.0B | $2.0B | $2.1B | $2.2B | $2.1B |
|---|
| $26.4B |
| $25.42B |
| +$2.06B |
| +8.83% |
| 2019 | $23.36B | ($385.00M) | (1.62%) |
| 2018 | $23.75B | +$898.00M | +3.93% |
| 2017 | $22.85B | ($142.00M) | (0.62%) |
| 2016 | $22.99B | +$1.33B | +6.14% |
